- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Viridium Pacific Group CEO Provides Update to Green Chip Stocks’ Jeff Siegel
Viridium Pacific (TSXV:VIR) CEO Jay Garnett recently conducted an interview with Green Chip Stocks Editor Jeff Siegel.
Viridium Pacific (TSXV:VIR) CEO Jay Garnett recently conducted an interview with Green Chip Stocks Editor Jeff Siegel regarding the company’s progress in clinical research studies related to cannabis.
According to Garnett, Viridium (which is soon to be called Experion) has sponsored one of the first Phase II and Phase III clinical research studies related to post-operative pain reduction. The study is one of the most advanced cannabis-related research projects in all of Canada. Viridium began generating revenue in September 2018 through its wholesale flower business, which has developed a reputation for high-quality products and sales service.
“We started with wholesale flower and quickly established a reputation for high-quality product and sales service. Our regular customers include Emerald Therapeutics, Tilray, High Point, to name a few. We have now entered into the Adult Use market with several Canadian provincial distributors. Whilst Experion was not the first to market, we were one of the fastest products to sell out with increased re-orders across the board,” said Jay Garnett, CEO of Viridium Pacific.
Garnett also went on to explain Viridium’s business strategy, which is aimed at generating multiple revenue streams and business opportunities. The company has established a strong reputation in B2B sales, offering clones to other licensed producers looking to establish their cultivation operations.
To read more of the conversation between Garnett and Siegel, click here.
Outlook Reports
Featured Cannabis Investing News Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2177.84 | +9.43 | |
Silver | 24.80 | +0.10 | |
Copper | 4.01 | +0.01 | |
Oil | 81.59 | +0.96 | |
Heating Oil | 2.67 | +0.03 | |
Natural Gas | 1.63 | -0.03 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.